T2 Biosystems (TTOO) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
T2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company Update
November 2, 2017 4:06 PM EDTSubmitted 510(k) Application to the FDA Requesting Market Clearance for T2Bacteria PanelYear over Year Quarterly Product Revenue Growth of 27.4%
LEXINGTON, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today operating highlights and financial results for the third quarter ended September 30, 2017. Â
 Third Quarter Business and Financial Performance Highlights:
Reported third quarter total revenue of $1.1 million, in line with guidance. Product revenue of $739,000, was a $159,000 or 27.4% increase from the... More